Sg3 Management, LLC Blueprint Medicines Corp Call Options Transaction History

Sg3 Management, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $1.13 Million - $1.75 Million	-25,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $1.35 Million - $2.75 Million	25,000 New	25,000 $1.6 Million
Q4 2021 Feb 15, 2022	SELL	$94.25 - $115.99 $5.66 Million - $6.97 Million	-60,100 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $2.84 Million - $3.84 Million	35,100 Added 140.4%	60,100 $6.18 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $2.07 Million - $2.53 Million	25,000 New	25,000 $2.2 Million

352

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.68B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.